A n 83-year-old man with a history of left lower extremity pleomorphic sarcoma diagnosed and surgically resected in 1998 with neoadjuvant radiotherapy (55-60 Gy), presented with a large and partially ulcerated cutaneous lesion in the region of prior radiation and surgical treatment (Fig. 1) . Six months earlier, the lesion appeared as a small ∼1 cm erythematous maculopapule that progressively enlarged. PET-CT revealed hypermetabolic foci localized to the cutaneous and subcutaneous tissues of the left calf corresponding to the location of the lesion (Fig. 2) . Biopsy showed primary cutaneous diffuse large B cell lymphoma, leg-type (PCDLBCL-LT). The patient was treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and achieved a complete tumor response.
PCDLBCL-LT is rare, with a much worse prognosis than other forms of cutaneous B cell lymphoma. 1 In contrast to this case, PCDLBCL-LT typically presents with red to bluish nodules or tumors on one or both legs. 1 The five-year survival rate is ∼50 %, due to dissemination to extracutaneous sites. 1, 2 PCDLBCL-LT development in the region of prior radiation therapy has not been previously reported. This case highlights that development of secondary cutaneous malignancies should be considered after the administration of high dose radiation therapy.
